These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7236312)

  • 21. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
    Góra-Tybor J; Robak T
    Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Psychotropic drugs and new 1,5-benzodiazepine analogs as antitumor agents].
    Werner W; Wohlrabe K; Gutsche W; Jungstand W; Römer W
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(5):637-42. PubMed ID: 6172326
    [No Abstract]   [Full Text] [Related]  

  • 23. The treatment of acute leukemia with continuous infusion L-Alanosine.
    Weick JK; Tranum BL; Morrison FS
    Invest New Drugs; 1983; 1(3):249-51. PubMed ID: 6678874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased tumor control rates in murine fibrosarcoma by combined therapy with L-alanosine and radiation.
    Hong SS; Alfieri AA; Kim SH; Kim JH
    Jpn J Cancer Res; 1989 Jun; 80(6):592-6. PubMed ID: 2503478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
    Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
    Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Animal experimental examination of a phase III study on the effect of the combination therapy of bruneomycin, cytostasan and prednisone].
    Nowak C; Arnold W; Henneberger G; Tanneberger S
    Arch Geschwulstforsch; 1983; 53(1):37-44. PubMed ID: 6344835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of platinum(II) choline complex on murine leukemias L1210 and P388.
    Ochocki J; Glinka R; Cieśliński M; Góra-Tybor J; Potemski P
    Pharmazie; 1997 Jul; 52(7):567-9. PubMed ID: 9266598
    [No Abstract]   [Full Text] [Related]  

  • 28. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
    Watanabe M; Komeshima N; Nakajima S; Tsuruo T
    Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Toxicologic study and experimental antitumor activity of rubidomycin (13,057 R.P.)].
    Maral R; Bourat G; Ducrot R; Fournel J; Ganter P; Julou L; Koenig F; Myon J; Pascal S; Pasquet J; Populaire P; de Ratuld Y; Werner GH
    Pathol Biol; 1967 Oct; 15(19):903-8. PubMed ID: 4296784
    [No Abstract]   [Full Text] [Related]  

  • 30. MTAP homozygous deletion: an Achilles heel of human cancers ready for clinical use?
    Capella G; Caldas C
    Cancer Biol Ther; 2005 Mar; 4(3):347. PubMed ID: 15876862
    [No Abstract]   [Full Text] [Related]  

  • 31. Antitumor activity of a new fluoropyrimidine derivative, 5'-deoxy-5-fluorouridine, against murine and human experimental tumors.
    Fujimoto S; Wang Y; Inoue K; Ogawa M
    Jpn J Cancer Res; 1985 Jul; 76(7):644-50. PubMed ID: 3161854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potentiation of the chemotherapeutic effect of 5-fluorouracil by combination with guanosine 5'-monophosphate.
    Iigo M; Nakajima Y; Kuretani K; Hoshi A
    Gan; 1983 Apr; 74(2):291-8. PubMed ID: 6305753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of L-alanosine (NSC 15353).
    Goldsmith MA; Ohnuma T; Spigelman M; Greenspan EM; Holland JF
    Cancer; 1983 Feb; 51(3):378-80. PubMed ID: 6821823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B; Jayaram HN; Johnson RK
    Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigations on the mechanisms of methotrexate resistance in a cisplatin-resistant L1210 murine leukemia cell subline.
    Wroblewski DH; Bhushan A; Xuan Y; Brinton BT; Tritton TR; Hacker MP
    Cancer Chemother Pharmacol; 1996; 37(4):337-42. PubMed ID: 8548879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of anthracyclines against an adriamycin (NSC-123127)-resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC-18334).
    Johnson RK; Ovejera AA; Goldin A
    Cancer Treat Rep; 1976 Jan; 60(1):99-102. PubMed ID: 826316
    [No Abstract]   [Full Text] [Related]  

  • 38. Antitumour activity of chlorimidazine on transplantable mouse tumour systems.
    Mircheva JJ; Pantev TP
    Chemotherapy; 1985; 31(6):472-5. PubMed ID: 4075859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alanosine (UCSD).
    Yu J
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1623-30. PubMed ID: 11763167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of fluoropyrimidine metabolism in L1210 cells by L-alanosine.
    Heimer R; Goldberg D; Cadman E
    Biochem Pharmacol; 1983 Jan; 32(2):199-206. PubMed ID: 6870949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.